Browse the corpus

Malakoplakia is a rare inflammatory condition that typically occurs in immunocompromised individuals and is thought to be secondary to a bactericidal defect in macrophages. Malakoplakia typically affects the urinary tract, but the involvement of nearly every organ system has been reported. This activity reviews the evaluation and treatment of malakoplakia and highlights the role of the interprofessional team in the care of patients with this condition. Objectives: Identify the etiology of malakoplakia. Assess the appropriate evaluation of malakoplakia. Differentiate the management options available for malakoplakia. Communicate interprofessional team strategies for enhancing care coordination to improve the recognition of malakoplakia. Access free multiple choice questions on this topic.

Malakoplakia is an uncommon, chronic granulomatous inflammatory condition that is usually found in immunocompromised population. First described by Michaelis and Gutmann in 1902, malakoplakia derives its name from the Greek terms μαλαχΟς (“malakos,” meaning soft) and πλαχες (“places,” meaning plaques) reflecting the characteristic gross appearance of the lesions.[1][2] Malakoplakia most frequently involves the urinary tract; however, extra-genitourinary involvement has been well documented, including the gastrointestinal tract, lung, brain, lymph nodes, adrenal glands, tonsils, conjunctiva, skin, bone, abdominal wall, pancreas, retroperitoneum, and female genital tract. The condition is commonly associated with underlying states of immune dysregulation or chronic illness, including solid organ transplantation, tuberculosis, sarcoidosis, allergic disorders, cytotoxic chemotherapy, acquired immunodeficiency syndrome, malignancy, corticosteroid therapy, alcohol abuse, poorly controlled diabetes mellitus, ulcerative colitis, and malnutrition.[3] It may arise in the setting of both infectious and noninfectious etiologies. Among infectious, Escherichia coli is the most frequently associated organism, although a variety of other bacterial pathogens have also been reported. Management strategies range from antimicrobial therapy to surgical resection, depending on the extent of disease and clinical context.[1]

The precise pathogenesis of malakoplakia remains incompletely characterized, representing a significant gap in our understanding of this distinctive chronic inflammatory disorder. Evidence strongly supports that malakoplakia arises from an acquired defect in macrophage bactericidal function. β-glucuronidase, a lysosomal hydrolase, contributes to the complete degradation of bacterial cell wall components, while cGMP functions as a crucial second messenger modulating microtubule dynamics and vesicular trafficking within the phagolysosomal system. This enzymatic and signaling deficit creates a permissive environment wherein pathogenic organisms persist within phagolysosomal compartments despite initial phagocytic internalization. The consequence of this functional impairment is the accumulation of partially degraded bacterial debris within macrophage cytoplasm, as the defective enzymatic machinery fails to achieve complete microbial clearance. The pathognomonic Michaelis-Gutmann bodies (MG) (calcified intracytoplasmic inclusions) are thought to represent the phagolysosomes that have not been exocytosed.[3] Malakoplakia is most commonly associated with infections caused by enteric gram-negative bacilli, particularly Escherichia coli and Klebsiella pneumoniae, which represent the predominant etiologic agents identified in reported cases. Nonetheless, a wide spectrum of additional microorganisms has been implicated, underscoring the opportunistic and polymicrobial potential of this condition. Other gram-negative organisms reported in association with malakoplakia include various Klebsiella species, Proteus species, Pseudomonas, Acinetobacter, Aerobacter, Salmonella, and Burkholderia species. Gram-positive bacteria have also been documented, such as Staphylococcus, Streptococcus, Enterococcus, Corynebacterium, and Rhodococcus species. Acid-fast bacilli, most notably Mycobacterium species, have likewise been linked to malakoplakia in select cases. Beyond bacteria, rare associations with fungal pathogens, including Paracoccidioides brasiliensis, as well as viral agents, have been described in isolated case reports, highlighting the broad range of potential infectious triggers.[4][3][5][6][7]

Malakoplakia is most commonly associated with infections caused by enteric gram-negative bacilli, particularly Escherichia coli and Klebsiella pneumoniae, which represent the predominant etiologic agents identified in reported cases. Nonetheless, a wide spectrum of additional microorganisms has been implicated, underscoring the opportunistic and polymicrobial potential of this condition. Other gram-negative organisms reported in association with malakoplakia include various Klebsiella species, Proteus species, Pseudomonas, Acinetobacter, Aerobacter, Salmonella, and Burkholderia species. Gram-positive bacteria have also been documented, such as Staphylococcus, Streptococcus, Enterococcus, Corynebacterium, and Rhodococcus species. Acid-fast bacilli, most notably Mycobacterium species, have likewise been linked to malakoplakia in select cases. Beyond bacteria, rare associations with fungal pathogens, including Paracoccidioides brasiliensis, as well as viral agents, have been described in isolated case reports, highlighting the broad range of potential infectious triggers.[4][3][5][6][7] Clinically, malakoplakia occurs with increased frequency in individuals with underlying states of impaired immunity or immune dysregulation. A variety of predisposing conditions have been documented, reflecting both systemic immunosuppression and chronic inflammatory or debilitating illnesses. These include solid organ transplantation with iatrogenic immunosuppression, chronic pulmonary tuberculosis, HIV/AIDS, and exposure to cytotoxic chemotherapy. Malakoplakia has also been reported in association with malignant neoplasms, poorly controlled diabetes mellitus, chronic alcohol abuse, and malnutrition, all of which may compromise host defenses and phagocytic function. Additionally, autoimmune and inflammatory conditions such as ulcerative colitis and certain allergic diseases have been described in affected patients, suggesting that both quantitative and qualitative defects in immune function may contribute to the pathogenesis.[7][6][3]

Epidemiological characterization of malakoplakia has been substantially limited by the rarity of this condition. Nonetheless, accumulated case series and retrospective analyses have revealed several distinctive demographic patterns. A pronounced sex predilection is evident in malakoplakia, though this varies considerably by anatomic site. Females demonstrate a markedly increased susceptibility to genitourinary tract involvement, with the bladder representing the most frequently affected visceral organ in this population. Conversely, cutaneous manifestations of malakoplakia exhibit a striking male predominance, occurring approximately twice as frequently in men compared to women.[7] Age distribution analysis indicates that malakoplakia predominantly affects adults in the fifth decade of life and beyond, with peak incidence observed in middle-aged to elderly populations. This age-related pattern is consistent with the recognized association between malakoplakia and immunocompromised states, as advancing age is frequently accompanied by subtle immune senescence and comorbid conditions that impair macrophage function. However, the disease spectrum extends to include rare pediatric cases, with documented occurrences in infants and young children. The absence of comprehensive epidemiological data represents a significant limitation in our current understanding of this entity. Existing reports derive predominantly from single-institution case series and literature reviews.[7][8]

The pathogenesis of malakoplakia remains incompletely elucidated, though current evidence implicates a fundamental failure of macrophage-mediated bacterial clearance as the central pathogenic mechanism. In early-stage or naturally occurring infections, disease chronicity appears to arise from the inability of either the offending pathogen or the host immune response to achieve effective elimination of the infectious agent. This persistent stimulus drives an ongoing, idiopathic inflammatory reaction characterized by the distinctive formation of intracytoplasmic, basophilic to eosinophilic inclusions known as MG bodies.[4] In vitro investigations employing human monocyte-derived cell lines have provided substantial mechanistic insight into this process. Upon microbial encounter, extracellular bacteria are internalized into phagosomes, which subsequently undergo delivery to endolysosomal compartments. Effective bacterial clearance is critically dependent upon robust lysosomal degradation; however, experimental observations demonstrate considerable heterogeneity in macrophage responses. While many phagocytosed organisms are successfully lysed within 48 hours without inducing significant host cell apoptosis, a notable subset of macrophages retains substantial quantities of undigested bacterial debris. This finding implicates lysosomal dysfunction, specifically inadequate release of β-glucuronidase, as a pivotal pathogenic factor.[9] The mechanism for this impaired degradation centers on the interdependence of β-glucuronidase and cyclic guanosine monophosphate (cGMP) in maintaining normal microtubular function and phagolysosomal activity. Dysfunction of either component disrupts the efficient processing of internalized organisms, resulting in progressive accumulation of partially digested bacterial material within macrophage cytoplasm. This retained intracellular debris is hypothesized to serve as the nidus for MGB formation, thereby establishing a direct mechanistic link between defective bacterial degradation and the granulomatous inflammation pathognomonic for malakoplakia. Additionally, activation of dimethyl-arginine dimethylaminohydrolase promotes aberrant calcium and iron deposition within affected tissues, further exacerbating the inflammatory response and contributing to progressive structural damage.[9]

The mechanism for this impaired degradation centers on the interdependence of β-glucuronidase and cyclic guanosine monophosphate (cGMP) in maintaining normal microtubular function and phagolysosomal activity. Dysfunction of either component disrupts the efficient processing of internalized organisms, resulting in progressive accumulation of partially digested bacterial material within macrophage cytoplasm. This retained intracellular debris is hypothesized to serve as the nidus for MGB formation, thereby establishing a direct mechanistic link between defective bacterial degradation and the granulomatous inflammation pathognomonic for malakoplakia. Additionally, activation of dimethyl-arginine dimethylaminohydrolase promotes aberrant calcium and iron deposition within affected tissues, further exacerbating the inflammatory response and contributing to progressive structural damage.[9] Clinical validation of these in vitro observations was provided by van Crevel et al. (1998), who documented profound monocyte dysfunction in malakoplakia patients, encompassing impaired bactericidal activity, defective phagolysosomal fusion, and diminished oxidative burst capacity. The consistent presence of MGBs in this clinical context reinforces defective intracellular killing as a cornerstone of disease pathogenesis and underscores the necessity of comprehensive immune assessment in patients presenting with chronic bacterial infections.[9] The recent report by Brownstein et al. describing rare coexisting sarcoidosis and malakoplakia introduces important diagnostic and pathophysiologic considerations. This unusual association suggests potential shared macrophage-related immunopathogenetic mechanisms between these two granulomatous processes.[9]

Histologic sections reveal a dense inflammatory infiltrate composed mainly of lymphocytes, plasma cells, histiocytes, and associated nuclear debris. The foamy histiocytes are enlarged with ecentric nucleaus having granular cytoplasm exhibiting variably sized, round cytoplasmic inclusions, many displaying concentrically layered structures with a central basophilic focus and surrounding pale halo. These inclusions are highlighted by periodic acid–Schiff, Prussian blue and Von Kossa stains, consistent with MG bodies demonstrating the characteristic features of malakoplakia. Von Kossa stain is considered the best for highlighting the MG bodies.[9][4]

The clinical presentation of malakoplakia is highly variable and depends on the organ system involved. Reported manifestations include gastrointestinal, genitourinary, hepatobiliary, cutaneous, soft tissue, and head and neck involvement, often with mass-forming lesions that mimic malignancy on imaging. Genitourinary involvement is among the most frequently described. Patients presenting with flank pain, urinary frequency, urgency, and intermittent gross hematuria. Imaging has demonstrated urinary tract masses or renal involvement. [10][3] Prostatic malakoplakia presents with urinary frequency, urgency, and dysuria, with elevated PSA and imaging revealing a mass in prostate.[11] Gastrointestinal tract involvement presents with chronic lower abdominal pain, altered bowel habits, tenesmus, intermittent loose stools mixed with mucus and blood, and rectal bleeding or features suggestive of bowel obstruction.[12] Appendiceal and ceccal malakoplakia have been misdiagnosed clinically as acute appendicitis or caecal carcinoma, with patients reporting nausea, vomiting, anorexia, unexplained weight loss, intermittent high fevers, and right-sided abdominal pain radiating to the lower back and right anterior thigh, where imaging demonstrated a mass-like lesion in the right iliac fossa with multiple enlarged nodules.[9][13] Gallbladder involvement presents with right upper quadrant abdominal pain.[14] In the pancreas, patients reported to have fevers, chills, dyspnea, and abdominal pain, imaging demonstrating an acute necrotic collection in the pancreas.[15] Esophageal malakoplakia associated with Barrett’s esophagus has presented with anemia and melena.[9] Perianal and perineal disease may present as nonhealing, complex fistulous disease refractory to surgical interventions.[5] Hepatic and hepatobiliary malakoplakia has presented with fever, chills, and abdominal pain; with complex mass and microabscesses on imaging studies.[16] Pelvic malakoplakia has manifested as chronic abdominal pain of vague location with associated lower urinary tract symptoms and recurrent urinary tract infections. Imaging showing mass in the adrenal gland, presacral soft tissue and ovaries.[4][2] Uterine/endometrial involvement manifests with postmenopausal bleeding and endometrial thickening.[17] Cervical malakoplakia presents as cervical mass.[18]

Pelvic malakoplakia has manifested as chronic abdominal pain of vague location with associated lower urinary tract symptoms and recurrent urinary tract infections. Imaging showing mass in the adrenal gland, presacral soft tissue and ovaries.[4][2] Uterine/endometrial involvement manifests with postmenopausal bleeding and endometrial thickening.[17] Cervical malakoplakia presents as cervical mass.[18] Head and neck involvement presents with flesh-colored exophytic mass at the gum area around the teeth, or with hoarseness of voice and cough if larynx is involved. Periorbital involvement has been described as a gradual, painless, firm fusiform swelling around the eyelid.[19][7][20] Malakoplakia can also present as an incidental retroperitoneal mass on surveillance imaging, reflecting deep-seated disease without a discrete external lesion.[21] Cutaneous lesions are rare. Clinically, these lesions can present as plaques, nodules, cobblestoning or ulcerated masses and frequently mimic neoplastic or granulomatous processes.[22][23] Collectively, malakoplakia is characterized by nonspecific systemic and local symptoms—such as fever, abdominal pain, diarrhea, rectal bleeding, dysuria, hematuria, weight loss, or focal swelling—combined with imaging findings of mass-like lesions, confluent microabscesses, or poorly defined soft tissue masses. Because of this broad and often tumor-like clinical and radiologic profile, lesions are frequently mistaken for malignancy or other inflammatory conditions until histopathologic evaluation provides a definitive diagnosis.

The diagnostic approach to malakoplakia is anchored in a thorough clinical history and physical examination. Cross-sectional imaging can refine the differential diagnosis; however, histologic confirmation via biopsy of the suspicious lesion remains indispensable, both to establish the diagnosis of malakoplakia and to exclude mimicking neoplastic, inflammatory, or infectious entities. The presence of MG bodies is the defining histopathologic feature. In addition, microbiologic cultures obtained from lesional tissue can provide adjunctive information to guide targeted antimicrobial therapy.[9]

Management of malakoplakia is centered on prolonged antibiotic therapy targeting intracellular microbes implicated in its pathogenesis. Fluoroquinolones (e.g., ciprofloxacin, ofloxacin), trimethoprim–sulfamethoxazole, tatracyclines and rifaximin are preferred due to their ability to achieve effective intracellular concentrations within macrophages and exert bactericidal activity. Reported cure rates with fluoroquinolone-based regimens range from approximately 66% to 100%. Initial empirical therapy may include agents such as amoxicillin–clavulanate or azithromycin, with subsequent adjustment guided by culture and susceptibility data.[24][9] Patients who are on immunosuppressive agents, their medication doses need to be adjusted.[25] Adjunctive agents, including bethanechol chloride, budesonide and ascorbic acid, have been employed to enhance intracellular cGMP levels, thereby augmenting lysosomal function and macrophage bactericidal capacity.[26] For certain organs involvement, surgical intervention is the only cure. Such as in appendiceal malakoplakia, appendectomy represents the definitive surgical modality, particularly in cases where conservative management is unsuccessful or when an associated mass lesion is identified.[27] More extensive surgical resection is reserved for refractory disease, the presence of obstructive symptoms, or scenarios in which malignancy cannot be excluded clinically or radiologically.[13] For urinary tract involvement, semi-annual radiologic and endoscopic surveillance is recommended to monitor disease evolution and evaluate response to treatment.[28] Increasing awareness among clinicians and promoting multi-center collaborative studies at both national and international levels are crucial to overcoming the diagnostic and therapeutic challenges posed by this rare entity. As an uncommon but important differential diagnosis in chronic infections and mass-forming lesions—particularly in immunocompromised patients—malakoplakia necessitates timely histopathologic recognition and prompt initiation of appropriate antibiotic therapy to minimize complications and avoid unnecessary surgical intervention.[9]

The differential diagnosis includes other infectious diseases, neoplastic, and reactive processes, including: Tuberculosis Cryptococcus Actinomycosis Botryomycosis Leishmaniasis Condyloma lata Cutaneous Crohn disease Sarcoidosis Foreign body granuloma Hidradenitis suppurativa Granular cell tumors Xanthomas Lymphoma[3][29][5][7][9][8][30][1]

Malakoplakia is typically considered a low-mortality condition; however, delayed or incorrect diagnosis can lead to significant morbidity, including organ dysfunction and sepsis. As a result, the overall clinical impact of malakoplakia is probably underestimated, partly because of its diagnostic complexity and the limited use of histologic evaluation in lesions that are initially misclassified as neoplastic.[31] Disease recurrence is frequently encountered, especially among immunocompromised patients. Without timely and appropriate treatment, malakoplakia may progress to permanent organ damage, particularly when vital structures such as the kidneys are affected. Although deaths are rare, they have been reported in association with severe complications, most notably sepsis and renal failure.[28] The clinical trajectory is influenced by the site and extent of involvement, coexisting comorbid conditions, and the patient’s response to medical and/or surgical therapy.[9] The prognosis of malakoplakia is heterogeneous. Some patients experience favorable outcomes with medical management alone, whereas others require surgical intervention, including procedures undertaken because the lesions mimic malignancy.[32] Early, accurate diagnosis and individualized management strategies are therefore critical to limiting complications and avoiding unnecessary or overly aggressive surgery.[33] In conclusion, malakoplakia generally carries a low risk of mortality; nonetheless, in immunocompromised individuals and in cases with visceral involvement (e.g., renal, pulmonary, or gastrointestinal), delays in diagnosis may precipitate serious complications such as sepsis and organ failure. Prompt recognition of the disease and early initiation of appropriate antibiotic therapy are key to preventing adverse outcomes.[9]

Disease recurrence is not uncommon, particularly in immunocompromised hosts. In the setting of delayed or suboptimal therapy, malakoplakia may progress to irreversible end-organ damage, especially when vital structures such as the kidneys are involved. Although overall mortality is low, fatal outcomes have been reported, typically in association with severe complications including sepsis and renal failure. The clinical trajectory is largely determined by the site and extent of involvement, the burden of underlying comorbidities, and the patient’s response to medical and/or surgical interventions.[9][24]

Patients with a history of immunosuppression, whether iatrogenic or secondary to another medical condition, should be warned about potential side effects or sequelae, such as malakoplakia. Patients should be instructed to inform their provider of any persistent, enlarging, or ulcerating lesions and for unresolved symptoms despite antimicrobial therapy.

Malakoplakia is a very rare inflammatory condition that typically occurs usually in immunocompromised individuals. Case reports from the literature have reported successful treatment with antibiotics, surgical excision, or a combination of both. Large randomized controlled studies do not exist for any specific treatments. Because malakoplakia can affect nearly every organ system, this condition is best handled with an interprofessional team approach. Such a team may include the provider managing the immunosuppressive condition or regimen (such as an infectious disease specialist, rheumatologist, primary clinician, oncologist, or transplant clinician), dermatologist, surgeon, and pharmacist. The initial provider may coordinate with the pharmacist for the ideal immunosuppressive regimen. When malakoplakia is suspected, a dermatologist, surgeon, radiologist or endoscopist may be consulted to perform a biopsy. Depending on the location and complexity of the lesion(s), an infectious disease specialist, dermatologist, and surgeon may be needed to maximize the management of the malakoplakia. Identifying and treating patients who are at risk early and keeping malakoplakia on the differential may reduce morbidity.